Evaxion A/S (NASDAQ:EVAX – Get Free Report) and 10x Genomics (NASDAQ:TXG – Get Free Report) are both medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their institutional ownership, profitability, analyst recommendations, risk, dividends, earnings and valuation.
Profitability
This table compares Evaxion A/S and 10x Genomics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Evaxion A/S | N/A | -68.82% | -24.12% |
| 10x Genomics | -11.89% | -11.50% | -8.93% |
Analyst Ratings
This is a summary of current ratings and target prices for Evaxion A/S and 10x Genomics, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Evaxion A/S | 1 | 0 | 3 | 1 | 2.80 |
| 10x Genomics | 3 | 9 | 4 | 0 | 2.06 |
Volatility and Risk
Evaxion A/S has a beta of 0.29, indicating that its stock price is 71% less volatile than the S&P 500. Comparatively, 10x Genomics has a beta of 2.18, indicating that its stock price is 118% more volatile than the S&P 500.
Insider & Institutional Ownership
11.0% of Evaxion A/S shares are held by institutional investors. Comparatively, 84.7% of 10x Genomics shares are held by institutional investors. 41.6% of Evaxion A/S shares are held by company insiders. Comparatively, 10.0% of 10x Genomics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.
Valuation and Earnings
This table compares Evaxion A/S and 10x Genomics”s revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Evaxion A/S | $3.34 million | 9.74 | -$10.57 million | ($0.39) | -10.00 |
| 10x Genomics | $610.78 million | 4.66 | -$182.63 million | ($0.62) | -36.29 |
Evaxion A/S has higher earnings, but lower revenue than 10x Genomics. 10x Genomics is trading at a lower price-to-earnings ratio than Evaxion A/S, indicating that it is currently the more affordable of the two stocks.
Summary
Evaxion A/S beats 10x Genomics on 9 of the 15 factors compared between the two stocks.
About Evaxion A/S
Evaxion Biotech A/S, a clinical-stage biotech company, engages in developing artificial intelligence-powered immunotherapies. The company develops EVX-01, which is in phase 2 global multi-center clinical trial for the treatment of metastatic melanoma; EVX-02, a DNA-based vaccine that is in Phase 1/2a trial designed to induce a therapeutic immune response in the adjuvant setting in patients with resected melanoma; and EVX-03, DNA-based cancer vaccine for the treatment of various cancers. Its programs also include some vaccines that are in pre-clinical stage, which includes EVX-B1 for the prevention of S. aureus-induced skin and soft tissue infections in patients undergoing elective abdominal hernia surgery; EVX-B2 to target diseases caused by N. gonorrhoeae; EVX-B3 for eliciting strong humoral antibody and cellular immune response to the bacterial pathogen; and EVX-V1, viral vaccine product candidate for targeting Cytomegalovirus. Evaxion Biotech A/S was incorporated in 2008 and is based in Horsholm, Denmark.
About 10x Genomics
10x Genomics, Inc., a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in the America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company provides chromium, chromium connect, and chromium controller instruments, microfluidic chips, slides, reagents, and other consumables products. Its single cell solutions runs on its chromium instruments, which include single cell gene expression for measuring gene activity and networks on a cell-by-cell basis; single cell gene expression flex; single cell immune profiling used to study the immune system; single cell Assay for Transposase Accessible Chromati (ATAC) solution to understand the epigenetic state; and single cell multiome ATAC + gene expression which enables simultaneous interrogation of both the RNA and chromatin accessibility, using ATAC in a single cell. The company also provides Visium platform which enables researchers to understand the spatial positions of biological analytes within tissues at high resolution; and Xenium platform for in situ analysis. It serves various academic, government, biopharmaceutical, biotechnology, and other institutions. The company was formerly known as 10X Technologies, Inc. and changed its name to 10x Genomics, Inc. in November 2014. 10x Genomics, Inc. was incorporated in 2012 and is headquartered in Pleasanton, California.
Receive News & Ratings for Evaxion A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evaxion A/S and related companies with MarketBeat.com's FREE daily email newsletter.
